Explore a New Direction for the Treatment of Diabetic Nephropathy by High-Throughput Sequencing

Yu Zhou; Qingyuan Li; Hui  Zhu; Zhihui  Yao; Yisheng  Wang; Zhui Ke

doi:10.62177/apjcmr.v2i4.1623

Authors

Yu Zhou Xiangshui County People’s Hospital
Qingyuan Li Xiangshui County People’s Hospital
Hui Zhu Xiangshui County People’s Hospital
Zhihui Yao Xiangshui County People’s Hospital
Yisheng Wang Xiangshui County People’s Hospital
Zhui Ke Shanghai Tenth People’s Hospital

DOI:

https://doi.org/10.62177/apjcmr.v2i4.1623

Keywords:

High-Throughput Sequencing, Diabetic Nephropathy, MiRNA, Molecular Docking

Abstract

Objective: To screen out miRNAs and mRNAs with targeted binding relationship, DKD-related signaling pathways and potential therapeutic drugs related to diabetic kidney disease ( DKD ), and to explore new directions for DKD treatment from the gene, signaling pathway and drug levels. Methods: Using the R language, differential miRNAs and mRNAs related to DKD were screened from the high-throughput sequencing data set of the GEO database. DKD-related signals were obtained by KEGG analysis. TargetScan database was used to further screen out miRNAs and mRNAs with targeted interaction. The DSigDB database was used to find out the drug components that had targeted effects on the proteins corresponding to the differential mRNA, and the binding stability of the two was verified by molecular docking. Results: A total of 17 miRNAs with a difference of more than 2 times, 68 mRNAs with a difference of more than 1.5 times, and 7 mRNAs with a difference of more than 4 times were obtained from the GEO database. KEGG analysis showed that DKD-related signaling pathways were IL-17 signaling pathway, NF-κB signaling pathway, TGF-β signaling pathway, TNF signaling pathway, etc. The TargetScan database further screened 7 miRNAs with targeted interaction and 26 mRNAs with targeted interaction. Through the DSigDB database, 51 drug components with potential treatment of DKD, such as acetovanillone, ademetionine, betacarotene, pterostilbene, and 5 corresponding target gene proteins were obtained : OLR1, IL1B, SERPINB2, CXCL3, ALAS2. Molecular docking showed that the drug components were stable in binding to the target gene protein. Conclusion: Hsa-miR-142-5p, hsa-miR-1225-3p, hsa-miR-513a-5p and OLR1, IL1B, ALAS2 mRNA can be used as key targets for the prevention and treatment of DKD. IL-17, NF-κB, TGF-β, TNF and other signaling pathways play an important regulatory role in the pathological process of DKD, and are the core related pathways for intervening DKD. In addition, natural active ingredients and compounds such as vanillone, adenosylmethionine, β-carotene, and pterostilbene showed good potential therapeutic value for DKD. The above research results can provide theoretical basis and new ideas for the exploration of the mechanism of DKD, targeted intervention and the development of new prevention and treatment strategies, and lay a research foundation for improving the clinical prognosis and alleviating the progression of DKD patients.

Downloads

Download data is not yet available.

References

Martinez Leon, V., Hilburg, R., & Susztak, K. (2026). Mechanisms of diabetic kidney disease and established and emerging treatments. Nature Reviews Endocrinology, 22(1), 21–35.

Li, J., Guo, K., Qiu, J., et al. (2025). Epidemiological status, development trends, and risk factors of disability-adjusted life years due to diabetic kidney disease: A systematic analysis of Global Burden of Disease Study 2021. Chinese Medical Journal, 138(5), 568–578.

Rong, J., Dai, Y., Zhang, B., et al. (2025). Diabetic kidney disease and aging: Focus on gut microbiota. Life Sciences, 381, 123999.

Verma, A., & Upadhyay, A. (2026). Diabetic kidney disease, biomarkers, and finerenone. Diabetes, Obesity and Metabolism, 28(4), 2582–2593.

Hu, Y., Ni, X., Chen, Q., et al. (2025). Predicting diabetic kidney disease with serum metabolomics and gut microbiota. Scientific Reports, 15(1), 12179.

Alur, V., Raju, V., Vastrad, B., et al. (2023). Bioinformatics analysis of next generation sequencing data identifies molecular biomarkers associated with type 2 diabetes mellitus. Clinical Medicine Insights: Endocrinology and Diabetes, 16, 733014963.

Yu, Y., Jia, Y., Wang, M., et al. (2021). PTGER3 and MMP-2 play potential roles in diabetic nephropathy via competing endogenous RNA mechanisms.BMC Nephrology, 22(1), 11–27.

Hou, Y., Li, Y., Wang, Y., et al. (2021). Screening and analysis of key genes in miRNA-mRNA regulatory network of membranous nephropathy. Journal of Healthcare Engineering, 2021, 1–13.

Hu, Y., Liu, S., Liu, W., et al. (2021). Bioinformatics analysis of genes related to iron death in diabetic nephropathy through network and pathway levels based approaches. PLOS ONE, 16(11).

Liang, J., Cheng, S., Song, Q., et al. (2025). Effect of mesenchymal stem cell–derived extracellular vesicles induced by advanced glycation end products on energy metabolism in vascular endothelial cells. Kidney International Reports, 10(1), 227–246.

Lin, M., Song, D., Zhang, S., et al. (2021). Dysregulation of miR-638 in diabetic nephropathy and its role in inflammatory response. Diabetology & Metabolic Syndrome, 13(1), 122.

Dragos, D., Enache, I. I., & Manea, M. M. (2025). Oxidative stress and nutritional antioxidants in renal diseases: A narrative review. Antioxidants, 14(7).

Gao, Y., Ji, Y., Zhang, X., et al. (2025). Xiaoyu Xiezhuo decoction improves diabetic kidney disease by regulating cysteine and methionine metabolism. Journal of Diabetes Research, 2025(1).

El-Marasy, S. A., Farouk, H., Khattab, M. S., et al. (2024). Beta-carotene ameliorates diabetic nephropathy in rats: Involvement of AMPK/SIRT1/autophagy pathway. Immunopharmacology and Immunotoxicology, 46(6), 763–772.

Keser, H., Bozkurt Girit, O., Majeed, M., et al. (2020). Pterostilbene administration improves the recovery potential of extremely low-frequency magnetic field in acute renal ischemia-reperfusion injury: An FTIR spectroscopic study. Turkish Journal of Biology, 44(1), 48–60.

Jiang, W., Gan, C., Zhou, X., et al. (2023). Klotho inhibits renal ox-LDL deposition via IGF-1R/RAC1/OLR1 signaling to ameliorate podocyte injury in diabetic kidney disease. Cardiovascular Diabetology, 22(1), 218–293.

Mahmoud, B., Abdel-Moneim, A., Negeem, Z., et al. (2022). The relationship between B-cell lymphoma 2, interleukin-1beta, interleukin-17, and interleukin-33 and the development of diabetic nephropathy. Molecular Biology Reports, 49(5), 3803–3809.

Saitoh, S., Okano, S., Nohara, H., et al. (2018). 5-aminolevulinic acid (ALA) deficiency causes impaired glucose tolerance and insulin resistance coincident with an attenuation of mitochondrial function in aged mice. PLOS ONE, 13(1), e0189593.

Wang, D., Chen, X., Fu, M., et al. (2019). Tacrolimus increases the expression level of the chemokine receptor CXCR2 to promote renal fibrosis progression. International Journal of Molecular Medicine, 44(6), 2181–2188.

Vasamsetti, S. B., Sadaf, S., Uddin, M. A., et al. (2026). Tissue-resident macrophage survival depends on mitochondrial function regulated by SerpinB2 in chronic inflammation. Nature Communications, 17(1), 1493.

Wang, J., Wang, X., Wang, M., et al. (2023). Clinical significance of interleukin 17 receptor E in diabetic nephropathy. International Immunopharmacology, 120, 110324.

Yang, C., Huang, F., Fang, H., et al. (2024). Jiawei Shengjiangsan’s effect on renal injury in diabetic nephropathy mice is investigated via the PI3K/Akt/NF-κB signaling pathway. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 17, 1687–1698.

Mei, M., Sun, H., Zhang, K., et al. (2026). Phellodendron amurense Rupr. polysaccharides protects against diabetic nephropathy via alteration of PI3K/GSK-3β/Nrf2/TGF-β/Smad signaling pathway and gut microbiota. Natural Products and Bioprospecting, 16(1), 13.

Aghaei-Zarch, S. M., Mahmoudieh, L., Miryounesi, M., et al. (2025). Investigation of TNF and related lncRNAs in diabetic nephropathy. Cytokine, 188, 156892.